Mark L. Jacobson

COO Mark L. Jacobson sells 4,750 shares for $1.1M at AXSM via scheduled 10b5-1 plan; retains 230,141 option shares

Mark L. Jacobson, Chief Operating Officer, executed 2 separate sales totaling 4,750 shares for $1,082,770.92 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings to zero while retaining 230,141 shares through stock option positions. The sales occurred at a blended average price of $227.95, below the current price of $255.17 and well below the 52-week high of $257.92. Jacobson's prior trades at AXSM show mixed 30-day outcomes (ranging from -3.4% to +11.9%) but consistently positive 90-day returns (ranging from +13.3% to +44.9%), suggesting the stock has tended to appreciate meaningfully in the months following his historical sales at this ticker. The company remains unprofitable despite strong revenue growth of +65.6% year-over-year and a substantial market cap of $13.1B, reflecting a high-growth but pre-profitability profile typical of biotech/therapeutics firms.

COO Mark L. Jacobson sold 35.4K AXSM shares at $161.88 (100% of holdings), raising $5.7M

Chief Operating Officer Mark L. Jacobson executed a complete liquidation of his 35,378 share position at $161.88, exiting with zero remaining holdings. This full sell-off of the COO's position is material given the officer's operational role at a $8.4B market-cap company currently unprofitable (net income $-47.2M against $171.0M quarterly revenue). His prior five sales at AXSM have consistently underperformed in timing, with 0 of 5 prior sells well-timed at the 90-day mark—most recently on 2025-09-22 he sold before the stock gained 31.6% in the following quarter. The current sale at $161.88, while above the 52-week low of $95.65, trades 13.3% below the 52-week high of $189.10, suggesting execution during recent pullback rather than continuation of prior upside.

AXSM COO Mark L. Jacobson sold 10,000 shares at $115.96; holds zero post-transaction; all prior AXSM sales underperformed (90d avg +13.8%, 0 of 3 well-timed).

Jacobson's sale of 10,000 shares ($1.2M) eliminates his entire position in AXSM and represents a complete exit. His prior three measurable AXSM sales (May 27, May 28, June 9, 2025) all saw the stock rise substantially over 90 days (+11.1%, +17.1%, +13.3%), meaning zero of those sales were well-timed. This transaction's timing relative to subsequent price action will establish whether the pattern continues. The company remains unprofitable ($-48.0M net income last quarter; annual revenue growth +42.5%), trading at $117.49 today (−14.7% from 52-week high), which adds context but does not confirm any forward directional signal from the trade itself.

COO Mark L. Jacobson sells entire 45.8K share stake (45.8K shares) for $5.2M at AXSM

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, executed 2 separate sales totaling 45,783 shares for $5,241,126.77 on 2025-09-16, eliminating his entire equity position post-transaction. The blended average price of $114.48 sits just below the current price of $116.62 (within 1.8%) but well below the 52-week high of $137.75, suggesting the sale occurred during a period of relative strength without capturing peak valuations. His prior trades at AXSM show a consistent pattern of poor 90-day timing (0 of 5 prior sells were well-timed at the 90-day mark), with post-sale returns averaging positive (+12.4% median from same-ticker history), indicating he has historically sold before further gains. This complete exit by a senior executive coincides with a company that generated $150.0M in quarterly revenue but reports negative net income of $-47,973,000.00, underscoring the tension between growth trajectory (+42.5% annual revenue growth) and profitability. The complete liquidation by a C-suite officer warrants scrutiny into whether this reflects conviction about valuation or structural business concerns beyond market price momentum.

COO Jacobson sells 25,000 AXSM shares at $110.44 for $2.8M; cuts holdings by 81.2% amid unprofitable fundamentals.

Mark L. Jacobson, Chief Operating Officer, executed a substantial sale of 25,000 shares on 2025-06-09 at $110.44, reducing his holdings from 30,783 to 5,783 shares—an 81.2% reduction. This represents a meaningful liquidation of a senior executive's position. At the same time, the company is materially unprofitable with net income of $-59,413,000.00 against quarterly revenue of $121,463,000.00, even as annualized revenue growth stands at +42.5%. The stock currently trades at $109.91, only 20.2% below its 52-week high of $137.75, suggesting the sale occurred near recent strength rather than at a depressed valuation. Notably, Jacobson executed two other sells at this ticker in the preceding 12 days (2025-05-27 and 2025-05-28), indicating a pattern of sequential liquidation in a window of high valuations.

COO Mark L. Jacobson sells 40,673 shares at blended $104.07 for $4.2M, reducing stake by -87.6%

Jacobson sold 20,673 shares at $104.66 on 2025-05-27 and 20,000 shares at $103.45 on 2025-05-28, for a combined $4,232,636.18, reducing his holdings from 46,456 to 5,783 shares. This represents a -87.6% reduction in his pre-transaction position executed over consecutive trading days. At AXSM specifically, his prior three open-market sells (2024-08-09, 2024-05-29, 2024-04-01) generated positive 90-day returns of +7.6%, +19.7%, and +4.2% respectively—meaning the stock rose after each sale and the insider did not benefit from favorable timing. The company is currently unprofitable (net income $-59,413,000.00 over the full fiscal year) despite strong annual revenue growth of +42.5%, and the stock is -25.2% from its 52-week high and -4.0% over the last 30 days. The concentrated liquidation of a large position by the COO merits scrutiny in the context of the company's ongoing losses and recent price momentum.

AXSM COO Mark L. Jacobson sold 47,739 shares (-89.2% of holdings) for $4.0M at $84.26 on 2024-08-09

Mark L. Jacobson, Chief Operating Officer, executed a substantial reduction in his Axsome Therapeutics stake, selling 47,739 shares (47.7K shares) for $4.0M on 2024-08-09, retaining only 5,783 shares (5.8K shares) post-transaction. The sale at $84.26 occurred near Axsome's 52-week high range ($57.42–$97.64), and the stock has since declined 14.9% to a current price of $83.09, though it remains up 14.6% over the 90-day period. Axsome is currently unprofitable with quarterly revenue of $87,166,000 but experiencing dramatic annual growth of +440.8%, and the company carries a $4.0B market cap despite negative net income of $-79,345,000 over its most recent full fiscal year. This near-complete liquidation of his insider position warrants investor attention given the size of the transaction and the company's cash-burn profile relative to its valuation.